SUBSCRIBE
SUBSCRIBE
News   Drug Development

Depomed, Inc. Announces Completion Of Phase I Clinical Trial With Gastroesophageal Reflux Disease Compound; Phase IIA Clinical Trial Planned

August 15, 2006 | 
1 min read

Depomed, Inc. (Nasdaq:DEPO) today announced that it has completed a Phase I clinical trial to evaluate the delivery and absorption of a compound currently used to treat gastroesophageal reflux disease (GERD).

Clinical research Phase I Phase II
MORE ON THIS TOPIC
IV infusion set on light blue background, top view. Space for text
Pipeline
BeiGene Scraps TIGIT Candidate After Underwhelming Lung Cancer Data
April 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Brain , concept idea art of thinking, surreal portrait painting, conceptual artwork, 3d illustration
Neurodegenerative disease
Denali Goes All In on Neuroscience’s Thorniest Hurdle: Crossing the Blood-Brain Barrier
April 2, 2025
 · 
5 min read
 · 
Dan Samorodnitsky
Cardiovascular disease
Merck’s Winrevair Cuts Morbidity, Mortality Risk by Over 75% in Phase III PAH Study
April 1, 2025
 · 
2 min read
 · 
Tristan Manalac
Climb up, hand help businessman build ladder
Diabetes
Vertex Cuts Diabetes Asset, but Analysts Keen on Phase III Option
March 31, 2025
 · 
4 min read
 · 
Annalee Armstrong